<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1FA5E2C-705B-4A74-9596-1A1CAC2A8375"><gtr:id>A1FA5E2C-705B-4A74-9596-1A1CAC2A8375</gtr:id><gtr:name>IBM</gtr:name><gtr:address><gtr:line1>IBM Corporation</gtr:line1><gtr:line2>1 New Orchard Road</gtr:line2><gtr:line4>Armonk</gtr:line4><gtr:line5>NY 10504-1722</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83241060-3BAD-499D-BA72-380013794CC6"><gtr:id>83241060-3BAD-499D-BA72-380013794CC6</gtr:id><gtr:name>Abbott</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EFA2059D-73E3-4989-9D54-188E5DB50EB6"><gtr:id>EFA2059D-73E3-4989-9D54-188E5DB50EB6</gtr:id><gtr:name>Cepheid</gtr:name><gtr:address><gtr:line1>904 Caribbean Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/523AAC69-F424-48B8-8597-E2F690B1F226"><gtr:id>523AAC69-F424-48B8-8597-E2F690B1F226</gtr:id><gtr:name>Foundation for Innovative New Diagnostics (FIND)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1E57BC3D-6462-4A13-87C4-899014DAAD05"><gtr:id>1E57BC3D-6462-4A13-87C4-899014DAAD05</gtr:id><gtr:name>Hain Lifescience GmbH</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A2EC0DF1-142D-422A-AB83-724ABEC8BE19"><gtr:id>A2EC0DF1-142D-422A-AB83-724ABEC8BE19</gtr:id><gtr:name>University of the Witwatersrand</gtr:name><gtr:address><gtr:line1>University of the Witwatersrand</gtr:line1><gtr:line2>WITS</gtr:line2><gtr:line3>2050</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A2EC0DF1-142D-422A-AB83-724ABEC8BE19"><gtr:id>A2EC0DF1-142D-422A-AB83-724ABEC8BE19</gtr:id><gtr:name>University of the Witwatersrand</gtr:name><gtr:address><gtr:line1>University of the Witwatersrand</gtr:line1><gtr:line2>WITS</gtr:line2><gtr:line3>2050</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>South Africa</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1FA5E2C-705B-4A74-9596-1A1CAC2A8375"><gtr:id>A1FA5E2C-705B-4A74-9596-1A1CAC2A8375</gtr:id><gtr:name>IBM</gtr:name><gtr:address><gtr:line1>IBM Corporation</gtr:line1><gtr:line2>1 New Orchard Road</gtr:line2><gtr:line4>Armonk</gtr:line4><gtr:line5>NY 10504-1722</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83241060-3BAD-499D-BA72-380013794CC6"><gtr:id>83241060-3BAD-499D-BA72-380013794CC6</gtr:id><gtr:name>Abbott</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EFA2059D-73E3-4989-9D54-188E5DB50EB6"><gtr:id>EFA2059D-73E3-4989-9D54-188E5DB50EB6</gtr:id><gtr:name>Cepheid</gtr:name><gtr:address><gtr:line1>904 Caribbean Drive</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/523AAC69-F424-48B8-8597-E2F690B1F226"><gtr:id>523AAC69-F424-48B8-8597-E2F690B1F226</gtr:id><gtr:name>Foundation for Innovative New Diagnostics (FIND)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1CC23DC2-3991-4123-B5F2-83C1F5793403"><gtr:id>1CC23DC2-3991-4123-B5F2-83C1F5793403</gtr:id><gtr:name>F. Hoffmann-La Roche AG</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1E57BC3D-6462-4A13-87C4-899014DAAD05"><gtr:id>1E57BC3D-6462-4A13-87C4-899014DAAD05</gtr:id><gtr:name>Hain Lifescience GmbH</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/191DC2AA-F75D-4956-836A-C8833DD54EDB"><gtr:id>191DC2AA-F75D-4956-836A-C8833DD54EDB</gtr:id><gtr:firstName>Rosanna</gtr:firstName><gtr:surname>Peeling</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B7754D0C-F1F4-4E25-960E-6CA190158DFD"><gtr:id>B7754D0C-F1F4-4E25-960E-6CA190158DFD</gtr:id><gtr:firstName>Wendy</gtr:firstName><gtr:otherNames>Susan</gtr:otherNames><gtr:surname>Stevens</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_16021"><gtr:id>DB2D661D-F4B0-44BB-B06D-41430061D6C6</gtr:id><gtr:title>Technology supported systems for rapid impact on TB control</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_16021</gtr:grantReference><gtr:abstractText>Delivery of diagnostic services that serve the population well depends upon the availability of high quality diagnostic tests and of laboratory systems that are able to prioritise efforts in regions of particular need and respond to changes in the distribution of that need. South Africa has pioneered widespread introduction of a new test for tuberculosis (TB) called Xpert MTB/RIF which runs on a platform called Genexpert that has capability both for connectivity to a central laboratory facility and for testing for things other than just TB. This means that the National Health Laboratory Service is able to identify where there are increases in people being diagnosed with TB, and potentially also follow trends in other infectious diseases such as HIV. In addition, this network provides the opportunity to test the performance of new and improved tests for infectious diseases, including TB, with the ultimate goal of improving patient care.</gtr:abstractText><gtr:technicalSummary>The National Priority Program (NPP) of the National Health Laboratory Service was formalized in 2010 to address the National Department of Health?s (NDoH) need to provide increased access to patient testing to enhance care programs, with a focus on HIV and TB and other opportunistic infections. Strength of this program is its national footprint of laboratory analyzers that are all interfaced via a laboratory information system (LIS). This data is reviewed centrally and provides the backbone to monitoring and evaluation of NDoH treatment programs. The LIS and other data connectivity tools, provides the basis for identifying trends in disease prevalence, ?hot spots? of transmission, the impact of interventions and regions of poor service coverage. In particular this group?s implementation model for pulmonary TB testing using the GeneXpert platform has become a globally accepted approach. These implementation models require refining to improve current practice (especially for MDR/XDR TB diagnosis), modification with the introduction of the more sensitive GeneXpert Ultra test and integration with HIV through exploration of the polyvalent capabilities of the GeneXpert platform and expansion to vulnerable populations. 

The anticipated outcomes of the three year project and collaboration are to implement the
mapping systems to impact on patient care and deliver models that will improve patient care and linkage to treatment as well as reduce costs while improving and integrating service delivery.

Three milestones have been identified: (i) primarily to deliver system mapping tools (a national dashboard for monitoring and evaluation; a real-time operational dashboard for improved laboratory service delivery; a novel real-time molecular epidemiology dashboard to target interventions); and secondarily (ii) to streamline diagnostic algorithms to increase rapid TB detection, drug resistance and reduce program costs; and (iii) to integrate TB and HIV service delivery using polyvalent diagnostic testing platforms to meet sustainable development goals.

Four goals have been identified for this study in order to achieve the milestones
1 - to optimize connectivity platforms to ensure optimal reporting of
relevant TB disease indicators and optimize ?real-time? laboratory quality indicators and thereby improve TB control. 

2 - to evaluate new diagnostics for TB and MDRTB to improve
patient diagnosis and develop cost-effective laboratory diagnostic and treatment algorithms.

3 - to further evaluate these diagnostic platforms for polyvalent
capabilities to integrate and optimize TB and HIV patient care and service. 

4 - to develop and propose policy using the connectivity mapping tools to optimize current services and models of new and integrated diagnostics to improve services.</gtr:technicalSummary><gtr:fund><gtr:end>2018-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>281170</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>IBM</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>IBM Research Zurich</gtr:department><gtr:description>Big data analysis for TB dashboard display</gtr:description><gtr:id>DEC71500-B4D4-4CA7-8B00-05FB48B1E64D</gtr:id><gtr:impact>In progress.</gtr:impact><gtr:outcomeId>58c9430fbbd9f8.06164038-1</gtr:outcomeId><gtr:partnerContribution>Artificial intelligence, data algorithms and visual displays.</gtr:partnerContribution><gtr:piContribution>Data accumulation through the laboratory information system and central data warehouse management. National program management that generates data.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cepheid</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Comparison of the Abbott RealTime MTB and GeneXpert MTB/RIF assays for the diagnosis of tuberculosis for improved patient care.</gtr:description><gtr:id>503B43FA-AC83-4B5E-A2A2-B932E9C44000</gtr:id><gtr:impact>In progress.</gtr:impact><gtr:outcomeId>58ca6657daf048.22691238-2</gtr:outcomeId><gtr:partnerContribution>Instruments, reagents and training.</gtr:partnerContribution><gtr:piContribution>Study management, provision of specimens, provisional data analysis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Global Fund</gtr:department><gtr:description>Expansion of HIV Viral Load Monitoring at Point of Care (Xpert HIV-1 VL)</gtr:description><gtr:id>C6690BA2-2AA0-4590-BA02-6470B5E512C0</gtr:id><gtr:impact>Provisional Point of Care Policy Document.
Training materials for staff, which will ultimately be distributed nationally.</gtr:impact><gtr:outcomeId>58ca61e81c6cb8.59701846-1</gtr:outcomeId><gtr:partnerContribution>Expert opinion, financial.</gtr:partnerContribution><gtr:piContribution>The Xpert HIV viral load assay evaluation showed that viral load monitoring can be performed in decentralized laboratories and extended VL testing for patient monitoring is being trialed at multiple remote clinics. Training manuals were prepared for staff training. In addition, a point of care policy document was prepared in collaboration with the NHLS and the National Department of Health and is currently under revision.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Foundation for Innovative New Diagnostics (FIND)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>FIND multi-centre evaluation of the Xpert MTB/RIF Ultra for TB diagnosis.</gtr:description><gtr:id>880D7F6B-BEC2-4ABD-842D-23761C613942</gtr:id><gtr:impact>WHO policy and recommendations in progress.</gtr:impact><gtr:outcomeId>58c9444159df37.99497055-1</gtr:outcomeId><gtr:partnerContribution>Policy for improved patient care.</gtr:partnerContribution><gtr:piContribution>As part of a 10-country study to evaluate the more sensitive Xpert Ultra sputum test for TB and show non-inferiority to existing Xpert MTB/RIF TB test, two clinical sites were established (Hillbrow and Thembaletu) and laboratory testing was performed at a dedicated clinical trials laboratory (CLS). This will result in improved diagnostics for TB care.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cepheid</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Cepheid HIV-1 Viral Load evaluation on 'off-label' specimens</gtr:description><gtr:id>DCE037D1-EEA9-45A7-9872-08E59E937E66</gtr:id><gtr:impact>In progress.</gtr:impact><gtr:outcomeId>58c945500d4a05.47603086-1</gtr:outcomeId><gtr:partnerContribution>Supply of Xpert HIV-1 VL cartridges and instrument for clinic for study duration, with the aim of further integrating HIV-TB diagnostics.</gtr:partnerContribution><gtr:piContribution>Optimisation of off-label specimen testing has been optimised. A clinical trial is approved to commence on 1 April 2017.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hain Lifescience GmbH</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Evaluation of the automated Fluorotype tuberculosis assay for TB drug resistance testing (first and second-line)</gtr:description><gtr:id>A1C2D80F-1BE3-4F99-8C84-EF411180669B</gtr:id><gtr:impact>In progress.</gtr:impact><gtr:outcomeId>58ca65a6045ed0.31834363-1</gtr:outcomeId><gtr:partnerContribution>Provision of instrument. Software upgrades based on early data analysis. Training of scientists.</gtr:partnerContribution><gtr:piContribution>Safety testing, provision of specimens; study is ongoing, but will require data analysis at a later stage. Software has been upgraded based on early testing.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cepheid</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Installation of the Cepheid C360 dashboard on National Priority Program field-based instruments</gtr:description><gtr:id>FF244FC9-C41A-44FA-B0C1-EB351DB65308</gtr:id><gtr:impact>In progress</gtr:impact><gtr:outcomeId>58ca62be249945.00539022-1</gtr:outcomeId><gtr:partnerContribution>Provision of the C360 dashboard.</gtr:partnerContribution><gtr:piContribution>Capabilities for medical informatics using the laboratory information system (LIS) are still being investigated and ways forward determined, but the C360 dashboard installation on the National Priority Program instruments in the field. Data management and analysis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>F. Hoffmann-La Roche AG</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Roche Prototype Molecular Test Evaluation</gtr:description><gtr:id>B29D46D9-351C-465E-9849-74AC2BCE2EA7</gtr:id><gtr:impact>In progress.</gtr:impact><gtr:outcomeId>58ca6424738045.69618492-1</gtr:outcomeId><gtr:partnerContribution>Provision of instrument, reagents and training.</gtr:partnerContribution><gtr:piContribution>Project management, evaluation of instrument, data management.Two sites were established with Dr Neil Martinson in Soweto and Klerksdorp for specimen colelction. The technology is still at the early developmental stage.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Abbott</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Abbott Diagnostics</gtr:department><gtr:description>Comparison of the Abbott RealTime MTB and GeneXpert MTB/RIF assays for the diagnosis of tuberculosis for improved patient care.</gtr:description><gtr:id>58A6C063-80B7-4EA0-8601-DBBC94030CD5</gtr:id><gtr:impact>In progress.</gtr:impact><gtr:outcomeId>58ca6657daf048.22691238-1</gtr:outcomeId><gtr:partnerContribution>Instruments, reagents and training.</gtr:partnerContribution><gtr:piContribution>Study management, provision of specimens, provisional data analysis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>AIDS 2016: TB pre-meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E2EAE8F4-F775-4718-A9A3-4E6C1BC2A72C</gtr:id><gtr:impact>The discussion around this presentation: &amp;quot;Access to second-line treatment for children diagnosed with Rifampicin-resistant tuberculosis in South Africa: a national retrospective cohort study&amp;quot; was lively and informative. Clinical staff dealing with the treatment of tuberculosis were particularly interested in options to improve access to the treatment for children in resource limited environments.</gtr:impact><gtr:outcomeId>58c90b4e76e4d8.10132439</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>African Society for Laboratory Medicine Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>85089D92-4BB2-4D1B-A792-D95627EB8961</gtr:id><gtr:impact>The presentation entitled: &amp;quot;The Spectrum of Use of the Xpert MTB/RIF test in the South AfricanNational GeneXpert Program&amp;quot;, enabled dissemination of knowledge to other African countries and generated interest regarding the previous and future directions of the Xpert MTB/RIF roll-out.</gtr:impact><gtr:outcomeId>58c8ff6e39b561.58336056</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ACTG Annual Meeting: Future Directions Session</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>29EA529B-5B4A-4344-9D96-2B83C174D9DC</gtr:id><gtr:impact>The presentation entitled: &amp;quot;Update on Line Probe Assay External Quality Assessment&amp;quot; disseminated knowledge on the progress of this product, now in the pilot phase. It will ultimately ensure quality assessment of laboratories performing the HAIN MTBDRplus assay to determine tuberculosis drug resistance patterns and there was great interest from the audience in the program.</gtr:impact><gtr:outcomeId>58c902e45f5393.36482698</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>African Society for Laboratory Medicine Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>52839A76-EE80-4D07-858E-D336C67D2F48</gtr:id><gtr:impact>The presentation entitled: &amp;quot;Has the threshold of case-detection with Xpert MTB/RIF been reached in South Africa?&amp;quot; ensured lively debate about the program locally and across Africa.</gtr:impact><gtr:outcomeId>58c900f28892f9.83328142</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Union Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1A940502-19ED-4036-9E5A-10B5BDEA4F69</gtr:id><gtr:impact>Presentation regarding the impact of big data analysis on TB control.</gtr:impact><gtr:outcomeId>58c9481bc672e3.10213737</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Support Team for TB Diagnostics in China</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>7FC225CF-5A3F-4FD7-A678-CC0654365F15</gtr:id><gtr:outcomeId>58c7b2326f92d6.30436100</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Costing of all TB laboratory tests: recommendations made to NHLS/NDoH, with particular focus on new testing assays and platforms</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>28EC1A57-CFF8-40D5-96FB-365D57AD28D8</gtr:id><gtr:outcomeId>58ca5f0cafb642.90678509</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Drafting of a Point-of-Care document for the South African National Department of Health (under revision)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EAB48C3E-0850-46B6-9253-01043F3CB0D9</gtr:id><gtr:outcomeId>58c9499fe2af29.97510365</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>The evaluation of the new Xpert Ultra TB test in collaboration with FIND is complete and preliminary data analysis shows the assay will be applicable to South Africa's TB program and increase detection of presumptive TB cases.</gtr:description><gtr:id>7E21DF5D-4AAF-406B-B8BA-A9DDACEFA098</gtr:id><gtr:impact>Not applicable</gtr:impact><gtr:outcomeId>58ca6913199a03.85438856</gtr:outcomeId><gtr:stage>Market authorisation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>FIND multi-country evaluation of the Xpert MTB/RIF Ultra</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:ukcrnIsctnId>PO-7210</gtr:ukcrnIsctnId><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The GeneXpert instruments are widely available in South Africa for tuberculosis diagnostics and clinical trials of the HIV-1 assays at point-of-care are ongoing. We are testing 'off-label' for both point-of-care and centralised laboratory testing to further increase the usability of the instrument for polyvalent HIV-TB testing.</gtr:description><gtr:id>30F0A482-F221-4004-BFB5-FB3F283A35B4</gtr:id><gtr:impact>In progress.</gtr:impact><gtr:outcomeId>58c94b124a33f3.94835900</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Cepheid HIV-1 Viral Load Evaluation on 'off-label' specimens</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>CBFB487B-917B-465E-8E0B-9ADA17397493</gtr:id><gtr:title>Impact of the GeneXpert MTB/RIF Technology on Tuberculosis Control.</gtr:title><gtr:parentPublicationTitle>Microbiology spectrum</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d94d08377cf913bb8e95ed5aeaab2a13"><gtr:id>d94d08377cf913bb8e95ed5aeaab2a13</gtr:id><gtr:otherNames>Stevens WS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2165-0497</gtr:issn><gtr:outcomeId>58ad6b566ddbf2.60638862</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1422D135-1306-4503-91A2-6A0BFAE2D85C</gtr:id><gtr:title>Performance of the Abbott RealTie MTB and MTB RIF/INH Assays in a Setting of High Tuberculosis and HIV Coinfection in South Africa.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7fb7c2a64ce792b51a369b678ab1787"><gtr:id>c7fb7c2a64ce792b51a369b678ab1787</gtr:id><gtr:otherNames>Scott L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>5a7d8c0a6767a2.71763606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54B8AC18-81A8-4E89-81ED-E52B9FA43562</gtr:id><gtr:title>Molecular Microbiology: Diagnostic Principles and Practices, 3rd Edition</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/730537ccfda3aaba761b84918d25790a"><gtr:id>730537ccfda3aaba761b84918d25790a</gtr:id><gtr:otherNames>Stevens, W.S.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:isbn>9781555819088</gtr:isbn><gtr:outcomeId>58ca5acf729878.98243138</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74D929CE-42E3-40A6-A9D8-91B13824C415</gtr:id><gtr:title>Diagnosis of opportunistic infections: HIV co-infections - tuberculosis.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c7fb7c2a64ce792b51a369b678ab1787"><gtr:id>c7fb7c2a64ce792b51a369b678ab1787</gtr:id><gtr:otherNames>Scott L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>58ad6b564c8f22.31584098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15CAAFE0-E0F9-4019-9526-DCC5A5D41CA0</gtr:id><gtr:title>Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbd842659f7a86b11bd7867e48ee5e2e"><gtr:id>dbd842659f7a86b11bd7867e48ee5e2e</gtr:id><gtr:otherNames>Dorman SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5a7d8c0b0845f7.99630812</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_16021</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>E4AF608A-CDB6-4CE6-AA10-95B3E043E22F</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>8.1  Organisation and delivery of services</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes><gtr:rcukProgramme><gtr:id>C11BDEA9-7D9D-4728-B6A9-31032921B328</gtr:id><gtr:text>Newton</gtr:text></gtr:rcukProgramme></gtr:rcukProgrammes></gtr:project></gtr:projectComposition></gtr:projectOverview>